Table 1 Tumors selected for DNA sequencing strategies, based on clinical response^a

From: Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy

WES^b (n= 51)		*Docetaxel responder*		*Docetaxel non-responder*		*Docetaxel not evaluable*
WES^b (n= 51)		CR	PR	SD	PD
*Epirubicin responder*	CR					2 (1)
*Epirubicin responder*	PR	2 (1)	6 (3)	13 (4)	2 (0)
*Epirubicin non-responder*	SD		8 (1)	15 (0)
*Epirubicin non-responder*	PD			2 (1)	1 (0)
Amplicon^c (n= 45)		*Docetaxel responder*		*Docetaxel non-responder*		*Docetaxel not evaluable*
Amplicon^c (n= 45)		CR	PR	SD	PD
*Epirubicin responder*	CR					1 (0)
*Epirubicin responder*	PR	4 (0)	2 (0)	9 (1)	2 (1)
*Epirubicin non-responder*	SD	1 (0)	3 (1)	21 (0)	1 (0)	1 (0)
*Epirubicin non-responder*	PD

Numbers in paratheses indicate patients with pCR at surgery
^aTumors selected as response outliers (response per RECIST) and with tumor tissue available for DNA extraction (n = 96/109)
^bWES whole exome sequencing
^cAmplicon: amplicon-based sequencing of 6-gene panel

Back to article page

ISSN: 1756-994X

Contact us

Submission enquiries: editorial@genomemedicine.com
General enquiries: info@biomedcentral.com